Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -58.1%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $18M | $14M | $16M | $5M | $20M | $84M | $65M | $15M | $3M | $6M | $8M |
| Enterprise Value | $10M | $6M | $13M | $13M | $19M | $65M | $19M | $4M | $-3551407 | $5M | $182610 |
| P/E Ratio → | -1.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.27 | 0.21 | 0.25 | 0.05 | 0.21 | 1.28 | 2.36 | 2.01 | 0.95 | 1.71 | 3.21 |
| P/B Ratio | 0.74 | 0.72 | 0.58 | 0.14 | 0.46 | 0.61 | 0.69 | 2.08 | 0.26 | 1.37 | 0.81 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.09 | 0.19 | 0.12 | 0.20 | 1.00 | 0.70 | 0.50 | -0.97 | 1.47 | 0.07 |
| EV / EBITDA | — | — | 2.45 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0% | 69.0% | 75.3% | 62.0% | 52.0% | 44.5% | 70.0% | 69.9% | 44.0% | 56.0% | 62.6% |
| Operating Margin | -11.8% | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -230.1% | -538.3% | -624.7% | -847.0% |
| Net Profit Margin | -20.4% | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -644.3% | -278.4% | -698.7% | -1099.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -47.2% | -40.8% | -119.6% | -50.1% | -26.7% | -459.9% | -116.9% | -319.6% | -219.3% |
| ROA | -11.2% | -11.2% | -12.3% | -12.4% | -53.9% | -27.8% | -14.5% | -169.1% | -56.5% | -114.4% | -132.4% |
| ROIC | -33.5% | -33.5% | -3.4% | -28.5% | -101.7% | -52.6% | -70.5% | -1029.1% | -307.5% | -577.4% | -316.3% |
| ROCE | -13.3% | -13.3% | -2.5% | -24.0% | -95.8% | -41.9% | -27.5% | -71.7% | -135.6% | -157.1% | -140.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.21 | 1.21 | 0.59 | 0.77 | 0.41 | 0.23 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | 3.20 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.42 | -0.13 | 0.19 | -0.03 | -0.14 | -0.48 | -1.56 | -0.52 | -0.20 | -0.80 |
| Net Debt / EBITDA | — | — | -0.70 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.71 | -2.71 | -1.11 | -2.44 | -0.26 | — | — | — | -23.81 | -7.88 | -4.13 |
Net cash position: cash ($31M) exceeds total debt ($23M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 | 2.62 | 2.87 | 2.79 | 0.84 | 1.00 |
| Quick Ratio | 1.07 | 1.07 | 0.80 | 0.88 | 0.76 | 0.81 | 2.27 | 2.60 | 2.40 | 0.48 | 0.95 |
| Cash Ratio | 0.49 | 0.49 | 0.32 | 0.33 | 0.30 | 0.45 | 1.67 | 2.06 | 2.07 | 0.22 | 0.90 |
| Asset Turnover | — | 0.53 | 0.55 | 0.78 | 0.70 | 0.25 | 0.18 | 0.21 | 0.17 | 0.21 | 0.11 |
| Inventory Turnover | 1.80 | 1.80 | 1.33 | 3.40 | 4.28 | 2.23 | 0.83 | 1.53 | 1.53 | 1.08 | 1.82 |
| Days Sales Outstanding | — | 171.31 | 131.74 | 98.34 | 81.98 | 156.70 | 74.41 | 86.80 | 57.72 | 59.83 | 23.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $6M | $3M | $1M | $840000 | $230000 | $38972 | $3328 | $117 | $22 |
Persistent operating cash burn
Based on current market data, AYTU trades at a price-to-sales multiple of 0.26, a valuation level that suggests investors are heavily discounting the company's future earnings potential relative to the broader specialty pharmaceutical sector and its own historical trading ranges observed in recent fiscal periods.
The depressed P/S ratio appears to reflect a market consensus that the company's current revenue base is not yet sustainable or scalable. This valuation implies that the market is pricing in significant execution risk regarding the ADHD portfolio's ability to overcome generic competition and PBM-driven margin compression.
As reported in financial statements, AYTU's ROIC has trended into negative territory, reaching -15.8% in 2026Q3, which indicates that the company is currently destroying shareholder value rather than compounding it through its specialized ADHD and pediatric product investments.
The persistent negative return on capital suggests that the firm's asset base, heavily weighted toward intangible assets from past acquisitions, is failing to generate sufficient operating income to justify the capital deployed. Investors should monitor whether future strategic shifts can improve asset utilization or if further impairment of the capital base is likely.
According to quarterly data, the company's cash conversion cycle has expanded to 109 days in 2026Q3, driven by high days sales outstanding and inventory levels that suggest significant friction in converting product shipments into realized cash flows within the current distribution network.
The elevated CCC relative to historical norms indicates that the company may be struggling with channel inventory management or delayed collections from payors. This inefficiency exacerbates the firm's liquidity constraints, as capital remains trapped in working capital rather than supporting core operations.
Based on reported figures, AYTU's interest coverage ratio has deteriorated to -9.32 in 2026Q3, signaling that the company's operating income is insufficient to cover its debt obligations, thereby increasing the reliance on external financing to maintain ongoing business operations.
While the D/E ratio of 0.65 appears manageable in isolation, the lack of positive operating cash flow makes the debt burden a significant risk factor. The company's ability to service its obligations appears highly dependent on its ability to access capital markets, which may become increasingly costly given the current financial trajectory.
The price-to-sales ratio is frequently misapplied to AYTU, as it obscures the significant impact of gross-to-net adjustments and rebate structures that fundamentally decouple headline revenue from the actual cash-generating potential of the company's specialized ADHD delivery technologies.
Analysts should prioritize cash-based metrics or adjusted EBITDA over P/S, as the latter fails to account for the high fixed-cost structure and the volatility of net revenue realization. Relying on P/S may lead to an overestimation of the company's intrinsic value by ignoring the underlying margin erosion caused by PBM formulary dynamics.
Includes 30+ ratios · 19 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AYTU stock.
Aytu BioPharma, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Aytu BioPharma, Inc.'s return on equity (ROE) is -58.1%. The historical average is -161.4%.
Based on historical data, Aytu BioPharma, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aytu BioPharma, Inc. has 69.0% gross margin and -11.8% operating margin.